Sutro Biopharma (STRO) Corporate presentation summary

Platform innovation and technology

• Proprietary platform enables site-specific conjugation using non-natural amino acids and click chemistry for uniform, stable ADCs.

• Platform allows increased flexibility in linker-payload combinations, supporting industry-leading pharmacokinetics and safety.

• Cell-free system ensures scalability from discovery to commercial scale with consistent quality.

• High-throughput antibody screening and Fc-silent design reduce interstitial lung disease risk.

• Optimized linker technology and tumor-selective cleavage minimize off-target toxicity and maximize efficacy.

Pipeline and clinical development

• Advancing single- and dual-payload ADCs targeting complex tumor antigens with limited competition.

• Three INDs planned in three years: STRO-004 (TF), STRO-006 (ITGB6), and STRO-227 (PTK7 dual-payload).

• Initial Phase 1 data for STRO-004 expected mid-2026; IND submissions for STRO-006 and STRO-227 anticipated in 2026.

• Multiple candidates progressing in parallel for large oncology market opportunities.

• Cash runway extends into at least Q2 2028.

STRO-004: Tissue factor-targeting ADC

• Engineered for robust exposure and efficacy, with 50x preclinical exposure vs approved TF ADC.

• Fc-silent antibody design reduces ILD risk; DAR 8 payload boosts potency.

• Demonstrates reduced bleeding risk and favorable in vitro tolerability compared to approved TF ADCs.

• Shows promising anti-tumor activity in multiple TF-expressing cancer models, with high disease control and response rates.

• Phase 1 trial ongoing in advanced solid tumors; initial data expected mid-2026.